These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 29128548)
21. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
22. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia. Ortega Martínez de Victoria E Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604 [No Abstract] [Full Text] [Related]
23. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Korman M; Wisløff T Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187 [TBL] [Abstract][Full Text] [Related]
24. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252 [TBL] [Abstract][Full Text] [Related]
25. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224 [TBL] [Abstract][Full Text] [Related]
26. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin. Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618 [TBL] [Abstract][Full Text] [Related]
27. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases. Lankin VZ; Tikhaze AK; Viigimaa M; Chazova IЕ Ter Arkh; 2018 Sep; 90(9):27-30. PubMed ID: 30701731 [TBL] [Abstract][Full Text] [Related]
30. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Ono T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H; J Cardiol; 2015 Oct; 66(4):353-8. PubMed ID: 25577723 [TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients. Shen T; James DE; Krueger KA Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850 [TBL] [Abstract][Full Text] [Related]
32. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037 [TBL] [Abstract][Full Text] [Related]
33. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202 [TBL] [Abstract][Full Text] [Related]
34. Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. Musunuru K Annu Rev Med; 2021 Jan; 72():447-458. PubMed ID: 33234004 [TBL] [Abstract][Full Text] [Related]
35. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease. Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773 [TBL] [Abstract][Full Text] [Related]
36. Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. Knowles JW; Howard WB; Karayan L; Baum SJ; Wilemon KA; Ballantyne CM; Myers KD Circulation; 2017 May; 135(22):2204-2206. PubMed ID: 28446516 [No Abstract] [Full Text] [Related]
37. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels. Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965 [TBL] [Abstract][Full Text] [Related]
38. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors. Ioannidis JPA JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115 [No Abstract] [Full Text] [Related]
39. Do PCSK9 inhibitors reduce cardiovascular events? Kolber MR; Nickonchuk T; Turgeon R Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099 [No Abstract] [Full Text] [Related]